Profile change history
A deterministic history of records added to PeptideScanner and preserved profile or record revisions connected through the reviewed Maridebart cafraglutide identity.
Before and after
We rewrote the profile summary to describe the cited study record more directly. The cited source and status did not change.
Collection chronology
Showing the latest 14 additions by PeptideScanner publication date; the complete connected record set remains available in Latest Research. Most recent addition: August 14, 2026.
PeptideScanner retained ClinicalTrials.gov record NCT07313761 at 2026-08-13T05:52:27.026Z. Its registry update date was 2026-08-07, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07684235 at 2026-08-13T05:52:27.017Z. Its registry update date was 2026-08-04, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07037433 at 2026-08-10T18:10:03.862Z. Its registry update date was 2026-07-24, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07037459 at 2026-08-10T18:10:04.222Z. Its registry update date was 2026-07-02, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.
PubMed lists PMID 42592044 in Antibody therapeutics as Journal Article, Review, with publication-date metadata of 2026-06-01 (day precision). PeptideScanner associated the retained record with the identity slug maridebart-cafraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained PubMed bibliographic metadata for PMID 41337722 at 2026-07-30T16:23:39.188Z. PubMed recorded a metadata revision date of 2026-03-04 and an Entrez history date of 2025-12-03. PeptideScanner associated this retained record with the identity slug maridebart-cafraglutide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 41337723 at 2026-07-30T16:23:39.188Z. PubMed recorded a metadata revision date of 2026-03-04 and an Entrez history date of 2025-12-03. PeptideScanner associated this retained record with the identity slug maridebart-cafraglutide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 41337724 at 2026-07-30T18:19:18.413Z. PubMed recorded a metadata revision date of 2025-12-03 and an Entrez history date of 2025-12-03. PeptideScanner associated this retained record with the identity slug maridebart-cafraglutide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained ClinicalTrials.gov record NCT06987695 at 2026-07-30T18:18:33.507Z. Its registry update date was 2025-12-17, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07226765 at 2026-07-30T16:19:03.046Z. Its registry update date was 2026-06-12, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07229157 at 2026-07-30T16:25:18.016Z. Its registry update date was 2026-01-23, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07225686 at 2026-07-30T16:19:03.064Z. Its registry update date was 2026-06-12, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07441252 at 2026-07-30T16:19:03.063Z. Its registry update date was 2026-06-18, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.
ClinicalTrials.gov lists a completed Maridebart cafraglutide study sponsored by Amgen.